Replimune Group, Inc.
REPL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001737953
In the last 90 days, Replimune Group, Inc. insiders filed 0 open-market purchases and 5 sales; 199 institutions reported holding it in 13F filings for Q2 2026, worth $1.06B in total; no superinvestor holds it.
13F holders, Q3 2022
Institutional positions in Replimune Group, Inc. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 106
- +4 vs. Q2 2022
- Shares held
- 40.8M
- +761.2K (+1.9%) vs. Q2 2022
- Total value
- $703.9M
- +$3.73M (+0.5%) vs. Q2 2022
- New holders
- 12
- 48 more added
- Sold out
- 8
- 26 more reduced
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting REPL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 199 | $1.06B |
| Q1 2026 | 180 | $619.2M |
| Q4 2025 | 165 | $775.2M |
| Q3 2025 | 163 | $347.5M |
| Q2 2025 | 175 | $752.1M |
| Q1 2025 | 167 | $799.3M |
| Q4 2024 | 157 | $943.2M |
| Q3 2024 | 144 | $766.7M |
| Q2 2024 | 149 | $638.1M |
| Q1 2024 | 150 | $547.8M |
| Q4 2023 | 140 | $556.8M |
| Q3 2023 | 127 | $970.9M |
| Q2 2023 | 141 | $1.27B |
| Q1 2023 | 140 | $949.0M |
| Q4 2022 | 135 | $1.31B |
| Q3 2022 | 106 | $703.9M |
| Q2 2022 | 102 | $700.2M |
| Q1 2022 | 107 | $665.0M |
| Q4 2021 | 99 | $1.05B |
| Q3 2021 | 101 | $1.05B |
| Q2 2021 | 110 | $1.34B |
| Q1 2021 | 108 | $1.06B |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Replimune Group, Inc.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock Inc. | 2,766,371 | $47.8M | 0.00% | +442,331+19.0% | Added |
| Atlas Venture Life Science Advisors, LLC | 3,108,300 | $53.7M | 5.92% | −101,327−3.2% | Reduced |
| Redmile Group, LLC | 3,645,309 | $63.0M | 2.44% | 00.0% | Unchanged |
| Baker Bros. Advisors LP | 3,893,843 | $67.2M | 0.44% | +302,762+8.4% | Added |
| Price T Rowe Associates Inc | 4,171,171 | $72.0M | 0.01% | −1,711,360−29.1% | Reduced |
| Omega Fund Management, LLC | 4,288,154 | $74.1M | 27.12% | −385,226−8.2% | Reduced |
| Bank of Montreal | 0 | $0 | 0.00% | −215,930−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −59,430−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −31,434−100.0% | Sold out |
| Quantbot Technologies LP | 0 | $0 | 0.00% | −5,980−100.0% | Sold out |
| Charter Oak Capital Management, LLC | 0 | $0 | 0.00% | −200−100.0% | Sold out |
| State of Wyoming | 0 | $0 | 0.00% | −137−100.0% | Sold out |
| Dark Forest Capital Management LP | 0 | $0 | 0.00% | −5−100.0% | Sold out |
| Federated Hermes, Inc. | 0 | $0 | 0.00% | −3−100.0% | Sold out |